Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines and clinical pathways for management of upper GI bleeding
2022	Malaysian Health Technology Assessment (MaHTAS)	Immunotherapy for PD-L1 positive advanced non-small cell lung cancer
2022	National Institute for Health and Care Excellence (NICE)	Filgotinib for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 792
2022	NIHR Health Technology Assessment programme	Assessing the efficacy and safety of methotrexate vs ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema in children Taskforce (TREAT) randomised controlled trial
2022	NIHR Health Technology Assessment programme	Moulded cast compared with K-wire fixation after manipulation of an acute dorsally displaced distal radius fracture: the DRAFFT 2 RCT
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Peripartum or postnatal care disparities and equity
2022	Malaysian Health Technology Assessment (MaHTAS)	Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for non-small cell lung cancer
2022	National Institute for Health and Care Excellence (NICE)	Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal). NICE technology appraisal guidance 793
2022	NIHR Health Technology Assessment programme	EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation
2022	Malaysian Health Technology Assessment (MaHTAS)	Robotic arm-assisted surgery in total hip arthroplasty, total knee arthroplasty and unicompartmental knee arthroplasty
2022	National Institute for Health and Care Excellence (NICE)	Diroximel fumarate for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 794
2022	WorkSafeBC	Clinical accuracy of rapid antigen tests for COVID-19
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Ambulatory blood pressure monitoring (ABPM) in the identification of circadian patterns in patients with arterial hypertension: evaluation of safety, effectiveness, and efficiency]
2022	National Institute for Health and Care Excellence (NICE)	Ibrutinib for treating Waldenstrom's macroglobulinaemia. NICE technology appraisal guidance 795
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Workplace violence in healthcare settings
2022	WorkSafeBC	Functional neurology as treatment for post-traumatic brain injury
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of the safety, efficacy/effectiveness, and efficiency of teleconsultation in primary care, and the organizational, ethical, social, and legal aspects linked to its use]
2022	National Institute for Health and Care Excellence (NICE)	Venetoclax for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 796
2022	Health Technology Wales (HTW)	Electronic blood management systems for blood transfusions
2022	WorkSafeBC	Dupuytren's contracture and wrist fractures
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of the safety, efficacy/effectiveness, and efficiency of stereotactic body radiation therapy (SBRT) in lung, prostate, and liver cancer]
2022	National Institute for Health and Care Excellence (NICE)	Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal). NICE technology appraisal guidance 797
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: evaluation of Synvisc and Synvisc One for the management of knee osteoarthritis]
2022	WorkSafeBC	Percussion therapy for neuropathic pain
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Stereotactic radiosurgery for the treatment of epilepsy, essential tremor, Parkinson's disease, glossopharyngeal and trigeminal neuralgia: synthesis of its efficacy, effectiveness, safety, and efficiency]
2022	National Authority for Assessment and Accreditation in Healthcare (INEAS)	[SKYRIZI® (Risankizumab) for the treatment of moderate to severe plaque psoriasis in adults : A rapid review]
2022	National Institute for Health and Care Excellence (NICE)	Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation. NICE technology appraisal guidance 798
2022	NIHR Health Technology Assessment programme	Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation
2022	WorkSafeBC	Ketamine infusion therapy for hyperalgesia and or central sensitivity pain
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Primary bariatric endoscopic techniques in adults with or without type 2 diabetes mellitus. Efficacy, effectiveness, and safety]
2022	National Institute for Health and Care Excellence (NICE)	Faricimab for treating diabetic macular oedema. NICE technology appraisal guidance 799
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: use of electrodiagnostic testing in the neurological investigation - electromyography and nerve conduction studies]
2022	National Institute for Health and Care Excellence (NICE)	Faricimab for treating wet age-related macular degeneration. NICE technology appraisal guidance 800
2022	Health Technology Wales (HTW)	Stereotactic ablative radiotherapy (SABR) for the treatment of renal cell carcinoma
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: KamRAB (human rabies immunoglobulin) – passive and transient postexposure prophylaxis of rabies infection]
2022	National Institute for Health and Care Excellence (NICE)	Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer. NICE technology appraisal guidance 801
2022	NIHR Health Technology Assessment programme	Oral nutritional interventions in frail older people who are malnourished or at risk of malnutrition: a systematic review
2022	National Institute for Health and Care Excellence (NICE)	Cemiplimab for treating advanced cutaneous squamous cell carcinoma. NICE technology appraisal guidance 802
2022	NIHR Health Technology Assessment programme	Determining optimal strategies for primary prevention of cardiovascular disease: systematic review of cost-effectiveness analyses in the United Kingdom
2022	National Institute for Health and Care Excellence (NICE)	Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 803
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Home enteral nutrition in older patients with severe protein-energy malnutrition after hip fracture]
2022	NIHR Health Services and Delivery Research programme	Understanding the potential factors affecting carers’ mental health during end-of-life home care: a meta synthesis of the research literature
2022	National Institute for Health and Care Excellence (NICE)	Teduglutide for treating short bowel syndrome. NICE technology appraisal guidance 804
2022	NIHR Health Technology Assessment programme	Shock-absorbing flooring for fall-related injury prevention in older adults and staff in hospitals and care homes: the SAFEST systematic review
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Conductive intravesical chemohyperthermia with mitomycin in non-muscle invasive bladder cancer: review of guidelines and ongoing research]
2022	National Institute for Health and Care Excellence (NICE)	Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides. NICE technology appraisal guidance 805
2022	NIHR Health Technology Assessment programme	Endovascular stent grafting and open surgical replacement for chronic thoracic aortic aneurysms: a systematic review and prospective cohort study
2022	National Institute for Health and Care Excellence (NICE)	Belimumab for treating lupus nephritis (terminated appraisal). NICE technology appraisal guidance 806
2022	Scottish Health Technologies Group (SHTG)	Closed loop systems and the artificial pancreas for type I diabetes mellitus (T1DM)
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Perinatal and infant mental health care models and pathways
2022	WorkSafeBC	Environmental exposure to respirable particles and estimated risk of sarcoidosis
2022	National Institute for Health and Care Excellence (NICE)	Roxadustat for treating symptomatic anaemia in chronic kidney disease. NICE technology appraisal guidance 807
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: next-generation sequencing (NGS) panels for muscle disease]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ixazomib (reassessment after the deadline: multiple myeloma, at least 1 prior therapy, combination with lenalidomide and dexamethasone)]
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Assessment and clinical management of self-harm in adolescence: evidence-based protocol]
2022	WorkSafeBC	Tinnitus and the COVID-19 vaccine
2022	Agency for Healthcare Research and Quality (AHRQ)	Acute treatments for episodic migraine
2022	National Institute for Health and Care Excellence (NICE)	Fenfluramine for treating seizures associated with Dravet syndrome. NICE technology appraisal guidance 808
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis by NAAT]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Delamanid (repeal of the exemption: pulmonary multi-drug resistant tuberculosis, ≥ 10 kg)]
2022	Malaysian Health Technology Assessment (MaHTAS)	Early cancer detection test for lung (EarlyCDT-Lung)
2022	WorkSafeBC	Vision therapy as treatment for traumatic brain injury: 2022 update
2022	National Institute for Health and Care Excellence (NICE)	Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease. NICE technology appraisal guidance 809
2022	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[The use of social media and electronic communication in the delivery of youth protection services to young people in difficulty and their families]
2022	NIHR Health Services and Delivery Research programme	Safety of disinvestment in mid- to late-term follow-up post primary hip and knee replacement: the UK SAFE evidence synthesis and recommendations
2022	Health Technology Wales (HTW)	Laryngeal biopsies in the outpatient setting in people with suspected head and neck dysplasia/cancer
2022	WorkSafeBC	Inpatient versus outpatient programs as treatment for PTSD
2022	National Institute for Health and Care Excellence (NICE)	Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. NICE technology appraisal guidance 810
2022	NIHR Health Technology Assessment programme	Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis
2022	WorkSafeBC	Oral collagen supplements for shoulder sprain strain
2022	Agency for Healthcare Research and Quality (AHRQ)	Antibody response following SARS-CoV-2 infection and implications for immunity: a living rapid review
2022	National Institute for Health and Care Excellence (NICE)	Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal). NICE technology appraisal guidance 811
2022	NIHR Health Technology Assessment programme	REVascularisation of Ischaemic VEntricular Dysfunction (REVIVED): a randomised comparison of percutaneous coronary intervention (with optimal medical therapy) vs. optimal medical therapy alone for heart failure secondary to coronary disease
2022	Gesundheit Osterreich GmbH (GOeG)	[Cost effectiveness of communication training for health care professionals]
2022	WorkSafeBC	Convergence insufficiency and COVID-19 infection
2022	National Institute for Health and Care Excellence (NICE)	Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 812
2022	NIHR Health Technology Assessment programme	Improving the prediction of metastatic disease in primary colorectal cancer: Prospective multicentre evaluation of a prognostic model of conventional predictive variables and novel variables derived from perfusion computed tomography (Perfusion CT)
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Bronchial thermoplasty in severe asthma]
2022	Malaysian Health Technology Assessment (MaHTAS)	First line targeted therapy for advanced hepatocellular carcinoma (aHCC)
2022	WorkSafeBC	Lose-dose naltrexone as treatment for post-COVID conditions
2022	National Institute for Health and Care Excellence (NICE)	Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors. NICE technology appraisal guidance 813
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Radiofrequency ablation for treatment of symptomatic uterine myomas]
2022	Scottish Health Technologies Group (SHTG)	vCreate Neuro for the diagnosis and treatment of adults and children with epilepsy and other neurological disorders
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Cerliponase Alfa - reassessment after the deadline (type 2 neuronal ceroid lipofuscinosis)]
2022	National Institute for Health and Care Excellence (NICE)	Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 814
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Mosunetuzumab (follicular lymphoma, after ≥ 2 prior therapies)]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Magnetic sphincter augmentation for gastrooesophageal reflux disease (Addendum to Commission E21-06)]
2022	National Institute for Health and Care Excellence (NICE)	Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 815
2022	NIHR Health Technology Assessment programme	A proportionate, universal parenting programme to enhance social-emotional well-being in infants and toddlers in England: the E-SEE Steps RCT
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Setmelanotide (obesity and control of hunger, POMC, PCSK1 or LEPR-deficiency obesity, ≥ 6 years)]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Magnetic sphincter augmentation for gastrooesophageal reflux disease]
2022	National Institute for Health and Care Excellence (NICE)	Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer. NICE technology appraisal guidance 816
2022	NIHR Health Technology Assessment programme	Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilisation: RCT and systematic review
2022	Agency for Care Effectiveness (ACE)	Revivent TC transcatheter ventricular enhancement system for ischemic heart failure
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Polatuzumab Vedotin (new therapeutic indication: diffuse large B-cell lymphoma (DLBCL), combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP))]
2022	National Institute for Health and Care Excellence (NICE)	Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence. NICE technology appraisal guidance 817
2022	NIHR Health Technology Assessment programme	Uterine artery embolisation versus myomectomy for premenopausal women with uterine fibroids wishing to avoid hysterectomy: the FEMME RCT
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Satralizumab (neuromyelitis optica spectrum disorders, anti-aquaporin-4IgG seropositive, ≥ 12 years)]
2022	Agency for Care Effectiveness (ACE)	Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (new therapeutic indication: follicular lymphoma, pretreated patients)]